Cisplatin is a widely used antitumor agent that induces aggressive cancer cell death via triggering cellular proteins involved in apoptosis. Here, we demonstrate that cisplatin effectively induces orphan nuclear receptor TR3 phosphorylation by activating Chk2 kinase activity and promoting cross talk between these two proteins, thereby contributing to the repression of intestinal tumorigenesis via apoptosis. Mechanistic analysis has demonstrated that Chk2-induced phosphorylation enables TR3 to bind to its response elements on the promoters of the BRE and RNF-7 genes, leading to the negative regulation of these two anti-apoptotic genes. Furthermore, the induction of apoptosis by cisplatin is mediated by TR3, and knockdown of TR3 reduces cisplatininduced apoptosis in colon cancer cells by 27%. The role of TR3 in cisplatin chemotherapy is further clarified in mouse models. In Apc min/1 mice, cisplatin inhibits intestinal tumorigenesis by 70% in a TR3 phosphorylation-dependent manner; however, the loss of TR3 function in Apc min/1 /TR3 2/2 mice leads to the failure of cisplatin-induced repression of tumorigenesis. Consistently, xenografts derived from TR3 knockdown colon cancer cells are insensitive to cisplatin treatment, whereas a significant curative effect (50% inhibition) is observed in xenografts with functional TR3. Taken together, our study reveals a novel cross talk between Chk2 and TR3 and sheds light on the mechanism of cisplatininduced apoptosis through TR3. Therefore, TR3 may be a new target of cisplatin for colon cancer therapy.
Introduction
Platinum-based compounds represent one of the main therapeutic options for colorectal cancer, and a better understanding of its mechanism is required for effective cancer therapy. Cisplatin is a platinumbased chemotherapy drug widely used for the treatment of many malignancies, including testicular, bladder, cervical, ovarian and lung cancers and lymphomas. Cisplatin is also used in combination with other anticancer drugs for cooperative therapy of colorectal cancers (1) . Cisplatin strongly induces apoptosis due to its ability to form bidentate intrastrand Pt-d(GpG) and Pt-d(ApG) adducts that block DNA replication and lead to severe lesions; thus, highly replicating tumor cells tend to be killed (2) (3) (4) . Although the specific mechanisms those trigger apoptosis in response to cisplatin have not been clearly defined, several signaling pathways and various proteins have been implicated in this process. Treatment with cisplatin induces p53 activity and subsequently regulates the expression of downstream genes such as Bax and Bcl-2 (5). It has also been reported that cisplatin induces apoptosis via JNK in non-small-cell lung cancer. However, when highly expressed, MKP-1 (a mitogen-activated protein kinase phosphatase) negatively regulates JNK activity and limits the effects of cisplatin in non-small-cell lung cancer (6) . Therefore, cisplatin can stimulate a wide network of signals through different pathways, with the resulting induction of many apoptosis-related genes.
Chk2 is a common element in DNA damage signaling. Chk2 participates in cellular processes, such as cell cycle arrest, apoptosis, stress detoxification and DNA damage repair. Chk2 is a serine/threonine checkpoint kinase that can be activated by phosphorylation of T68 in an ATM-dependent manner (7) . Activated Chk2 then inactivates cyclin-dependent kinases (Cdks) by regulating Cdc25, Wee1 and p53 and inhibits cell cycle progression (8) . As a key protein in cell cycle regulation, Chk2 is also implicated in cell apoptosis. Chk2, in response to cisplatin, may induce p53 activation by phosphorylating p53, consequently leading to renal cell apoptosis (9) , indicating that Chk2 is intricately involved in the regulation of apoptosis via phosphorylation.
The nuclear orphan receptor TR3 (also known as Nur77 or NGFI-B) is a product of an immediate early gene and belongs to the steroid/ thyroid/retinoid nuclear receptor superfamily (10) . TR3 is involved in a variety of biological processes, such as cell proliferation, differentiation and apoptosis. The subcellular localization of TR3 is a key element in determining its biological function. TR3 mediates cell proliferation when functioning as a transcription factor in the nucleus (11) . Once cancer cells receive apoptotic stimuli, TR3 translocates from the nucleus to the mitochondria and induces cytochrome c release and initiates cell apoptosis (12, 13) . Recently, more evidence has suggested that TR3 also regulates the transcription of apoptosisassociated genes by binding to their promoters (14, 15) . We have discovered that an anti-apoptosis gene called brain and reproductive organ-expressed (BRE) protein may be specifically regulated by TR3 at the transcriptional level when gastric cancer cells are treated with the TR3 agonist Csn-B (16) , suggesting that TR3 also functions as a transcription factor to promote apoptosis.
TR3 activity has been shown to be regulated by phosphorylation (17) . The phosphorylation of Ser95 by JNK is thought to trigger TR3 degradation through the ubiquitination/proteasome pathway (18) . In PC12 cells, the phosphorylation of TR3 on Ser105 by TrK/Ras/mitogen-activated protein kinase promotes TR3 translocation from the nucleus to the cytoplasm, resulting in mitochondrial localization and apoptotic induction (19) . Akt has been shown to phosphorylate TR3 at Ser351 and inhibit its DNA-binding ability in the nucleus (20, 21) . Additionally, Akt phosphorylates cytoplasmic TR3 to inhibit its mitochondrial targeting (22) . Thus, the phosphorylation of TR3 may be associated with its activity, nucleocytoplasmic translocation and protein stability.
Previous studies have reported that cisplatin regulates the activity of nuclear receptors in different ways. In neuroblastoma cells, cisplatin inhibits hormone binding to the glucocorticoid receptor (GR) by disrupting the interaction between GR and Hsp90, leading to the inhibition of GR-mediated transcription. This inactivation of GR results in its proteasome-dependent degradation (23) . The orphan receptor pregnane X receptor (PXR) can be downregulated in response to cisplatin at both the messenger RNA (mRNA) and the protein levels via an unknown mechanism. However, cisplatin improves PXR binding to its responding element on the multiple drug resistance promoter and enhances coactivator AIB1 (amplified in breast cancer 1) recruitment to PXR/PXR responding element complexes, thus positively regulating multiple drug resistance (24) .
To explore the potential role of TR3 in cisplatin-induced apoptosis in colon tumorigenesis, we performed a series of in vivo and in vitro experiments. We show that TR3 is phosphorylated by Chk2 when colon cancer cells are exposed to cisplatin, and this modification causes TR3 to suppress the transcription of anti-apoptotic genes downstream, thereby strongly promoting cisplatin-induced apoptosis.
The in vivo data further verify that TR3 is involved in cisplatin therapy in Apc min/þ mice and xenograft models. The loss of TR3 function significantly abolishes the inhibitory effect of cisplatin on tumor incidence and xenograft proliferation. Therefore, our study not only shows a novel relationship between Chk2 and TR3 in response to cisplatin, resulting in gene regulation and cell apoptosis, but also identifies TR3 as a relevant mediator of the cisplatin-induced repression of colon tumorigenesis.
Materials and methods
Cell culture, transfection and stable cell line generation Human colon cells SW620 and human embryonic kidney cells 293T were purchased from the American Type Culture Collection (Rockville, MD).
The transfection of 293T cells was performed using the calcium phosphate precipitation method (25) . SW620 cells were transfected using the Turbofect transfection kit (Fermentas, St Leon-Rot, Germany).
The TR3-specific small interfering RNA (siRNA) expression vectors were generated by cloning the target sequence (si-TR3: 5#-GCATTATGGTGTCCG-CACATT-3#) into the siRNA expression vector pSuper (OligoEngine, Washington, DC). Plasmids encoding siRNA were introduced into SW620 cells, and stably transfected cells were selected using 0.5 mg/ml G418 (Sigma, St Louis, MO).
Histological and biochemical analysis in the Apc min/þ mouse model All animals were maintained at Xiamen University Laboratory Animal Centre (Xiamen University, China) in accordance with institutional guidelines. TR3 knockout C57BL/6 mice and Apc-mutated (Apc
) C57BL/6 mice were purchased from The Jackson Laboratory (Bar Harbor, ME). Mice were euthanized after cisplatin treatment, and intestinal tumors were counted and measured. Segments of intestinal tissue fixed in 10% neutral buffered formalin were processed, sectioned and stained with hematoxylin and eosin. Intestinal tissue used for the extraction of RNA and protein was excised. The phosphorylation level of TR3 was detected using western blotting, and the mRNA levels of BRE and RNF-7 were determined using reverse transcription-polymerase chain reaction.
TUNEL staining in tumor xenografts
Male nude mice (BALB/c, 4 weeks old) were purchased from the Laboratory Animal Center, Shanghai, China. For the tissue terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate-biotin nick end labeling assay (TUNEL), tumor sections were fixed in paraformaldehyde, and TUNEL staining was performed according to the protocol provided with the Cell Death Detection Kit (KGA7042; KeyGEN, China).
Other methods
Details of the other routine methods used, including RNA extraction and reverse transcription-polymerase chain reaction, construction of lentivirus siRNA vector, co-immunoprecipitation, western blot analysis, glutathione-S-transferase pull-down assay, flow cytometric assays, analysis of luciferase activity, chromatin immunoprecipitation (ChIP) assay, DNA affinity precipitation assay, are provided in the Supplementary Materials and Methods, available at Carcinogenesis Online.
Results

Cisplatin-induced TR3 expression correlates with its phosphorylation
To investigate the role of cisplatin in the regulation of TR3 expression, western blot analysis was first performed. In SW620 cells, TR3 protein expression was induced by cisplatin in dose-and time-dependent manners ( Figure 1A) . A similar induction in response to cisplatin was also found in 293T cells transfected with HA-TR3 (Supplementary Figure S1A is available at Carcinogenesis Online). However, the We further investigated whether this increased TR3 expression in response to cisplatin was due to a change in the TR3 degradation rate. Cycloheximide was used to block the in vivo protein synthesis of SW620 cells. The half-life time (the time required for 50% of the level of a protein to be degraded) of endogenous TR3 was almost 6 h. However, with cisplatin treatment, the half-life of TR3 was extended to .12 h (Supplementary Figure S1C is available at Carcinogenesis Online). Thus, cisplatin delays the degradation of TR3.
The exact mechanism of cisplatin-induced TR3 protein expression is unclear. It has been reported that cisplatin induces the phosphorylation of certain proteins at serine and threonine sites (9, 26, 27) . TR3 is a heavily phosphorylated protein (17) . Therefore, we suspected that cisplatin may induce TR3 phosphorylation. To test this, we used specific serine and threonine antibodies to monitor the potential phosphorylation of TR3. Using TR3 immunoprecipitates from SW620 cells, cisplatin indeed induced the phosphorylation of threonine but not serine in TR3 at the concentration of 10 lM ( Figure 1B ). Similar result was also obtained in 293T cells transfected with HA-TR3 (Supplementary Figure S1D is available at Carcinogenesis Online). Consistently, in the total cell lysates, TR3 expression levels were elevated in the presence of cisplatin ( Figure 1B ; Supplementary Figure S1D is available at Carcinogenesis Online). Therefore, it is possible that cisplatin-induced TR3 protein expression may correlate with TR3 phosphorylation.
To further confirm this possibility, we constructed several TR3 deletion mutants ( Figure 1C , top) and transfected them into 293T cells. The deletion of 85 aa from the N-terminus (D2) did not influence cisplatin-induced threonine phosphorylation, but a further deletion of 8 aa (D3) totally abolished the threonine phosphorylation of TR3 induced by cisplatin ( Figure 1C , bottom). This result suggests that the phosphorylation in response to cisplatin might occur within the region of residues 85-93 at the N-terminus of TR3. Sequence analysis of this region revealed only one threonine, located at position 88 ( Figure 1D , left). Therefore, we constructed a point mutant (T88A) of full-length TR3 to determine its phosphorylation status in response to cisplatin treatment. When this point mutant was transfected into 293T cells, cisplatin no longer induced the phosphorylation or expression of TR3. As a negative control, a nearby threonine mutation, T143A, showed the same phosphorylation status in response to cisplatin as full-length TR3 ( Figure 1D , right). Taking these data together, we conclude that cisplatin-induced TR3 protein expression correlates with TR3 phosphorylation.
Cisplatin-activated Chk2 interacts with and phosphorylates TR3
How does cisplatin induce TR3 phosphorylation and which kinase is involved in this process? To answer these questions, SW620 cells were pretreated with various kinase inhibitors before cisplatin stimulation. Phosphorylation assays showed that the Chk2 inhibitor obviously inhibited cisplatin-induced TR3 phosphorylation and protein expression, whereas other inhibitors were nearly ineffective ( Figure 2A ). Chk1 and Chk2 inhibitors were used to further confirm this finding. Again, the Chk2 inhibitor but not Chk1 inhibitor largely inhibited the phosphorylation level of TR3 in response to cisplatin (Supplementary Figure S2A is available at Carcinogenesis Online). Moreover, when Chk2 was knocked down in SW620 cells (Supplementary Figure S2B is available at Carcinogenesis Online), cisplatin no longer increased the phosphorylation and protein levels of TR3 ( Figure 2B ). Hence, Chk2 but not other kinases is selectively involved in cisplatin-induced TR3 phosphorylation.
We further analyzed the effect of Chk2 kinase activity on TR3 phosphorylation. The phosphorylation of T68 and D347 in Chk2 activates Chk2 activity after DNA damage, whereas the T68A and D347A point mutants of Chk2 lead to Chk2 inactive (28) . In addition, Chk2 itself possesses an autoactivating activity when overexpressed in cells or bacteria (29) . Indeed, when co-transfected with Chk2, the phosphorylation and protein levels of TR3 were dramatically increased, but the two kinase-inactive mutants of Chk2 did not show this effect ( Figure 2C ). Therefore, the kinase activity of Chk2 is required for increasing the phosphorylation and protein levels of TR3.
If the Chk2 kinase is important for TR3 phosphorylation, Chk2 must form a protein complex with TR3. To test this possibility, a co-immunoprecipitation assay was performed. In the absence of cisplatin, endogenous Chk2 could not be detected in TR3 immunoprecipitates, but it was readily detectable after cisplatin stimulation ( Figure 2D , left), indicating an activated interaction of TR3 and Chk2 in response to cisplatin at endogenous levels. A parallel experiment was performed to test the interaction between ectopically expressed HA-TR3 and Flag-Chk2. In the HA-TR3 immunoprecipitates, Chk2 was detected as a faint band, probably due to its active feature, and cisplatin further enhanced this interaction (Supplementary Figure S2C is available at Carcinogenesis Online). To determine the direct binding of Chk2 to TR3 in vitro, a glutathione-S-transferase pull-down assay was performed. Similar to the positive control b-catenin-TR3 association, glutathione-S-transferase-Chk2 also efficiently pulled down His-TR3 ( Figure 2D, right) . Moreover, confocal microscopy clearly indicated that the distribution of Chk2 overlapped more with TR3 in the nucleus in the presence of cisplatin (Supplementary Figure S2D is available at Carcinogenesis Online). Therefore, Chk2 directly interacts with TR3. However, Chk2 T68A or D347A failed to interact with TR3 under cisplatin stimulation (Supplementary Figure S2F is available at Carcinogenesis Online).
Next, we clarified the domain of TR3 that interacts with Chk2. Deletion assays indicated that D1 and D2 of TR3 interacted with Chk2, whereas D3 and D4 failed to do so (Supplementary Figure S2E is available at Carcinogenesis Online). Thus, aa 85-93 in TR3 are important for Chk2 binding. Since T88 is located within this interaction region, it suggests that Chk2 phosphorylation of TR3 may result from their binding. We therefore used T88A of TR3 to test this possibility. Although the phosphorylation of T88A by Chk2 was completely abolished ( Figure 2E , left) even in the presence of cisplatin ( Figure 1D , right), Chk2 still bound to the T88A mutant and this interaction could be enhanced by cisplatin ( Figure 2E, right) . Thus, it is probably that T88 of TR3 is responsible for Chk2 phosphorylation but not for Chk2 binding.
TR3 promotes cisplatin-induced apoptosis through Chk2 phosphorylation
Because cisplatin is a well-known apoptosis-inducing drug, we investigated the biological significance of TR3 in cisplatin-induced apoptosis and the role of Chk2 phosphorylation in TR3 function. First, we constructed a TR3 knockdown cell line (TR3/KD) (Supplementary Figure-S3A is available at Carcinogenesis Online) by stably expressing siRNA in SW620 cells. SW620 cells (TR3/WT) showed notable changes in their morphology and density when exposed to cisplatin ( Figure 3A ). More shrunken and floating cells were observed with fewer viable cells after cisplatin treatment, suggesting the occurrence of apoptosis. In contrast, most of the TR3/KD SW620 cells had no significant changes in phenotype regardless of cisplatin treatment. The nuclei of apoptotic cells were further visualized using 4#,6-diamidino-2-phenylindole staining. As expected, large proportions of apoptotic nuclei showed nuclear chromatin condensation and nuclear fragmentation in TR3/WT cells in response to cisplatin stimulation, whereas cisplatin did not effectively induce apoptosis in TR3/KD cells ( Figure 3B ). Flow cytometric measurements of apoptotic rates indicated that the treatment of TR3/WT cells with cisplatin resulted in a significant increase in apoptosis, and .40% of cells died in response to 20 lM cisplatin. In contrast, TR3/KD cells were more resistant to cisplatin, and 84% of the cells were still viable ( Figure 3C ). These results demonstrate that TR3 participates in cisplatin-induced apoptosis.
To evaluate the effect of TR3 phosphorylation by Chk2 on cisplatininduced apoptosis, TR3 and its point mutant (T88A) that cannot be phosphorylated by Chk2 were separately expressed in SW620 cells.
Role of TR3 in cisplatin-induced apoptosis
After treatment with cisplatin, the number of apoptotic cells in the TR3-transfected group increased from 4.02 to 60.85%. However, the apoptotic rate of cells expressing T88A was only 18.74% even in the presence of cisplatin, much less than that of non-transfected SW620 cells ( Figure 3D , top), suggesting that T88A mutant of TR3 may have a dominant-negative effect on cisplatin-induced apoptosis. In contrast, T88E, that mimics TR3 phosphorylation at T88, efficiently induced apoptosis of SW620 cells without cisplatin treatment (Supplementary Figure 3SB is available at Carcinogenesis Online). These observations suggest an important role for phosphorylated TR3 in apoptosis, probably through the activation of Chk2 by cisplatin. We further used Chk2 inhibitor to pretreat SW620 cells. After that, the cisplatin-induced apoptosis was almost abolished (from 3.94 to 7.63%) even overexpressing TR3 in SW620 cells (from 2.52 to 6.94%). Similarly, knockdown of Chk2 also abolished cisplatin-induced apoptosis (from 4.37 to 8.81%) (Figure 3D, bottom) . A series of results strongly support the hypothesis that Chk2-induced phosphorylation is a prerequisite for TR3 to enhance cisplatin-induced apoptosis. It is worth to note that knockdown of TR3 did not influence the cisplatin-induced Chk2 kinase activity (Supplementary Figure 3SC is available at Carcinogenesis Online), suggesting that TR3 acts as a downstream factor of Chk2 in cisplatin-induced apoptosis.
Cisplatin represses TR3 downstream anti-apoptotic target genes
To identify downstream genes regulated by TR3 in cisplatin-induced apoptosis, we performed Gene Chip analysis (our unpublished results) and selected three anti-apoptotic genes, BRE, RNF-7 and HSPB-1, for further analysis. BRE is an anti-apoptotic protein that inhibits the mitochondrial apoptotic pathway (30,31) ; RNF-7 represses caspase activation when cells undergo apoptotic stress (32) and HSPB-1 is a stress-induced apoptosis inhibitor (33). The results indicated that Fig. 2 . Cisplatin-activated Chk2 binds to and phosphorylates TR3. (A) TR3 is phosphorylated by Chk2. SW620 cells were pretreated with different kinase inhibitors, including Chk2 inhibitor (1 lM), ATM inhibitor (1 lM), JNK inhibitor (10 lM), Gö6976 (protein kinase C inhibitor, 1 lM), PD98059 (mitogenactivated protein kinase inhibitor, 10 lM), SB202190 (p38 mitogen-activated protein kinase inhibitor, 10 lM) and wortmannin (phosphatidylinositol 3-kinase inhibitor, 1 lM), as indicated for 1 h and followed by cisplatin treatment (10 lM, 8 h). Immunoprecipitated TR3 was normalized, and the phosphorylation status of TR3 was determined using western blotting. (B) Cisplatin-activated Chk2 is critical for TR3 phosphorylation. Si-Chk2 was introduced into SW620 cells by lentivirus transfection system, and the cells were treated with cisplatin (10 lM, 8 h). Then, TR3 was immunoprecipitated and the phosphorylation levels of Thr were detected. (C) Kinase activity of Chk2 is essential for TR3 phosphorylation. Chk2 and its point mutants T68A or D347A were transfected into 293T cells with TR3. The phosphorylation status of TR3 was detected as described above. (D) Chk2 interacts with TR3 in vivo and in vitro. Left: after 8 h of treatment with cisplatin (10 lM), SW620 cells were harvested, and endogenous TR3 was immunoprecipitated using a TR3 antibody. The immunoprecipitates were then examined by western blotting using a Chk2 antibody (Cellsignal) to determine endogenous TR3-Chk2 interaction. Right: glutathione-S-transferase-Chk2 was incubated with His-TR3 protein and then subjected to Coomassie Brilliant Blue staining to visualize the Chk2 protein and western blotting using an anti-His antibody (Roche) to evaluate the TR3 protein. The interaction between glutathione-S-transferase-b-catenin and His-TR3 was used as a positive control. (E) Chk2 interacts with but does not phosphorylate TR3 T88A. Flag-Chk2, together with TR3 or its point mutant T88A, were transfected into 239T cells and treated with cisplatin as indicated (40 lM, 8 h) . The interaction between T88A and Chk2 was detected using a co-immunoprecipitation assay (right), and the phosphorylation status of TR3 or T88A was detected using western blotting (left).
mRNA levels of BRE and RNF-7 but not HSPB-1 were reduced by cisplatin in a time-dependent manner in SW620 cells, whereas cisplatin did not regulate the mRNA levels of these genes when TR3 was knocked down. Moreover, reintroduction of HA-TR3 into TR3/KD SW620 cells rescued the inhibitory effect of cisplatin on mRNA levels of these genes (Supplementary Figure S4A is available at Carcinogenesis Online). Similarly, the protein levels of BRE and RNF-7 were also suppressed by cisplatin in a TR3-dependent manner (Supplementary Figure S4B is available at Carcinogenesis Online). These data thus identify two novel downstream factors regulated by cisplatin, probably through TR3 mediation.
To determine whether cisplatin regulates these genes via TR3 at the transcriptional level, the promoter activities of BRE and RNF-7 were assessed by luciferase assays. Cisplatin significantly inhibited the promoter activities of these two genes in SW620 cells, whereas it failed to exert such an effect when TR3 was knocked down. When TR3 was reintroduced into TR3/KD cells, the inhibitory effect of cisplatin on BRE and RNF-7 promoter activities was clearly observed again ( Figure 4A ). Thus, TR3 is an upstream regulator of BRE and RNF-7. Promoter sequence analysis revealed several potential NGFI-B responding element (NBRE) located in both the BRE and the RNF-7 promoters. This suggested that TR3 may bind to the promoters of BRE/RNF-7 and regulate the transcription of these genes. To test this, we performed ChIP assays in SW620-or HA-TR3-transfected 293T cells and found that cisplatin obviously promoted TR3 targeting to the NBRE on the BRE promoter and the NBRE-like sequence within the P1 region but not the P2 region of the RNF-7 promoter ( Figure 4B ; Supplementary Figure S4C is available at Carcinogenesis Online). Similarly, DNA affinity precipitation assays also revealed that TR3 could bind to the NBRE in the BRE and RNF-7 promoters but not negative controls (mutations of the NBRE sites) in response to cisplatin ( Figure 4C ). In accordance, when the NBRE sites were mutated on BRE and RNF-7 promoters, cisplatin failed to inhibit the promoter activities of these genes ( Figure 4D ). This cisplatin-induced inhibition might be due to the recruitment of co-repressor to the BRE or RNF-7 promoter by TR3, as when TR3 was knocked down, none of N-CoR was recruited to these promoters even in the presence of cisplatin ( Figure 4E) . Therefore, the binding of TR3 to the specific NBRE (or NBRE-like) sites and subsequent recruitment of corepressor to the BRE and RNF-7 promoters is important for cisplatin to downregulate the transcription of these two genes.
We then evaluated the correlation between TR3 phosphorylation and its regulation of the BRE and RNF-7 genes. The T88A mutant not only lost its binding ability to the NBRE-like sequence in the P1 region of the RNF-7 promoter but also failed to recognize the NBRE on the BRE promoter (Supplementary Figure S4C is available at Carcinogenesis Online). In addition, when TR3 was reintroduced into TR3/KD SW620 cells, the inhibitory effect of cisplatin on the reporter gene activities of RNF-7 and BRE were clearly observed, whereas the T88A mutant failed to do so ( Figure 4F ). The mimic mutant of phosphorylation T88E efficiently repressed the promoter activities of BRE and RNF-7 without cisplatin treatment ( Figure 4E) . Consistently, Fig. 3 . TR3 is essential for cisplatin-induced cell apoptosis. (A) Morphological changes in wild-type (TR3/WT) and TR3 knockdown (TR3/KD) SW620 cells in response to cisplatin. Cells were treated with cisplatin for 48 h at different concentrations and then observed using phase contrast microscopy. (B and C) TR3 is required for cisplatin-induced apoptosis. TR3/WT and TR3/KD SW620 cells were treated with cisplatin at different concentrations. After 48 h of treatment, apoptotic cells were stained with 4#,6-diamidino-2-phenylindole (B), and apoptotic rates were determined using flow cytometry (C). SW620 cells that were transfected with scrambled siRNA were used as a negative control. (D) The phosphorylation of TR3 by Chk2 is essential for cisplatin-induced apoptosis. Top: TR3 or its point mutant T88A was transfected into SW620 cells and then treated with cisplatin (20 lM, 48 h). The percentages of apoptotic cells were determined using flow cytometry. Bottom: SW620 cells were transfected with TR3 or si-Chk2. After pretreatment with Chk2 inhibitor for 1 h, followed by cisplatin (20 lM, 48 h), the apoptotic rates were determined by flow cytometry.
Role of TR3 in cisplatin-induced apoptosis Fig. 4 . Cisplatin regulates the transcription of BRE and RNF-7 through TR3. (A) Cisplatin regulates the transcription of BRE and RNF-7 reporters via TR3. The promoter regions of the BRE and RNF-7 genes containing NBRE or NBRE-like sequences were amplified and then subcloned into a luciferase reporter construct to generate pLuc-BRE or pLuc-RNF-7 reporters. Different cell lines, including TR3/WT and TR3/KD SW620 cells or TR3-transfacted TR3/KD SW620 cells were transfected with pLuc-BRE or pLuc-RNF-7 reporters and treated with cisplatin (10 lM, 12 h), then the activity of the reporters was determined using luciferase assays and normalized to the b-galactosidase activity. The basal level of transcriptional activity was normalized to 1. (B) Endogenous TR3 binds to the NBRE (or NBRE-like) sequence on the BRE and RNF-7 promoters. SW620 cells were treated with cisplatin (10 lM, 8 h), and ChIP assays were performed to show TR3 recruitment to the NBRE (or NBRE-like) sequence on the promoters of BRE and RNF-7. (C) TR3 binds to the NBRE (or NBRE-like) sequence on the BRE and RNF-7 promoters. SW620 cells were treated with cisplatin (10 lM, 8 h), and nuclear extracts were prepared. The oligonucleotides corresponding to the sequence from -1019 to -995 bp of RNF-7 and from -1617 to -1590 bp of BRE were used as probes, whereas mutants of the NBRE sequence (AAACCACA for BRE and TGTTTATT for RNF-7) were used as negative controls. DNA affinity precipitation assay was performed as described in Materials and methods. (D) TR3-DNA binding is essential for cisplatin-induced transcriptional suppression of BRE and RNF-7. The reporter pLuc-BRE, pLuc-RNF-7 or their mutants on the NBRE sequence was separately expressed in SW620 cells. After cells were treated with cisplatin (10 lM, 12 h), luciferase assays were performed. (E) Cisplatin promotes TR3 recruitment of N-CoR to the BRE and RNF-7 promoters. SW620 cells were treated with cisplatin (10 lM, 8 h), and N-CoR was immunoprecipitated by its specific antibody (Santa Cruz Biotechnology). The levels of N-CoR targeting to the promoters were then determined by ChIP assays. (F) The phosphorylation of TR3 is important for cisplatin to suppress the transcriptional activity of BRE and RNF-7. TR3 or its point mutants T88A and T88E was transfected into TR3/KD SW620 cells with pLuc-RNF-7 or pLuc-BRE reporter. Cisplatin treatment and luciferase assays were performed as described in (D). All transfections were performed in three independent assays, and the data represented the means ± standard deviations. (G) Cisplatin-induced apoptosis of SW620 cells is negatively correlated with BRE and RNF-7. Left: SW620 cells transfected with si-BRE or si-RNF-7 were cultivated with cisplatin (20 lM) for 48 h, and the percentages of apoptotic cells were determined. Right: SW620 transfected with HA-BRE or HA-RNF-7 as indicated were treated with cisplatin (20 lM, 48 h). The percentages of apoptotic cells were determined using flow cytometry. Figure S4D is available at Carcinogenesis Online). Thus, phosphorylation of T88 by cisplatin is important for TR3 to repress BRE and RNF-7 expression.
T88E directly inhibited expression of BRE and RNF-7 as cisplatin did (Supplementary
Finally, we tested whether the repression of BRE and RNF-7 leads to apoptosis induced by cisplatin. As expected, knockdown of BRE or RNF-7 alone (Supplementary Figure S4E is available at Carcinogenesis Online) distinctly induced apoptosis of SW620 cells without cisplatin stimulation (Figure 4G, left) . In contrast, overexpression of HA-BRE or HA-RNF-7 protected SW620 cells from cisplatininduced apoptosis ( Figure 4G, right) . Together, these results indicate that the downregulation of BRE and RNF-7 mediated by TR3 is critical for cisplatin-induced apoptosis.
The role of TR3 in cisplatin-repressed colon carcinogenesis To further determine the role of TR3 in cisplatin therapy in vivo, we utilized a widely used Apc min/þ mouse model that contains a truncating mutation in the Apc gene and spontaneously develops intestinal adenomas (34) . Stereomicroscopic images of adenomas formed in the intestines of mice clearly indicated a statistically significant reduction ($70%) in the numbers of intestinal adenomas in cisplatin-treated Apcmin/þ mice compared with the controls. Although Apc min/þ /TR3 À/À crossed mice developed much more intestinal adenomas than Apc min/þ mice, which is consistent with our previous finding (35) , there was no statistically significant difference in the numbers of polyps formed or tumors between control and cisplatin-treated Apc min/þ /TR3 À/À mice ( Figure 5A ). These in vivo results strongly demonstrate a potential clinical significance of TR3 as a cisplatin target.
Histological evaluation of the adenomas indicated dysplasia on the intestinal surface epithelium in different groups ( Figure 5B) . Most of the adenomas in Apc min/þ mice were exophytic lesions with irregular glands that were raised above the mucosal surface and lined with atypical epithelial cells. Cisplatin treatment effectively reduced the adenoma frequency, leading to fewer polyps in most sections of the intestine. However, no difference was found in abnormal glandular architecture with epithelial dysplasia between cisplatin-treated Apc min/þ /TR3 À/À mice and control mice, showing that TR3 is required for the cisplatin suppression of intestinal carcinogenesis.
To evaluate the importance of TR3 phosphorylation, intestinal tissue lysates were analyzed using antibodies specific for serine or threonine phosphorylation. In the cisplatin-treated group, the threonine phosphorylation and protein levels of TR3 in the intestines (containing adenomas) of Apc min/þ mice were greater compared with control mice ( Figure 5C ). Furthermore, cisplatin treatment resulted in the downregulation of BRE and RNF-7 expression in Apc min/þ mice; however, in Apc min/þ /TR3 À/À mice, TR3-dependent suppression of BRE and RNF-7 expression was not observed, even with cisplatin stimulation ( Figure 5D ). These results suggest a role of TR3 in mediating the suppression of carcinogenesis by cisplatin.
Cisplatin inhibits the tumor growth of xenografts via TR3
We assessed how TR3 influences the therapeutic effects of cisplatin in a xenograft tumorigenesis model. Wild-type and TR3/KD SW620 cells were injected into nude mice to generate tumors. As shown in Figure 6A , the xenograft growth of SW620 cells (left side) was significantly reduced in volume upon treatment with cisplatin, while the xenografts driven from TR3/KD cells (right side) showed slightly smaller sizes in response to cisplatin treatment. The tumor weight decrease in response to cisplatin was $50% (P , 0.05) for SW620 xenografts and 15.9% (P 5 0.342) for TR3/KD SW620 xenografts.
TUNEL staining of paraffin sections of tumors showed extensive apoptosis in cisplatin-treated SW620 xenografts compared with the control, whereas there was no obvious difference in TR3/KD xenografts before and after cisplatin treatment ( Figure 6B ). Similar to the in vitro data, TR3 was also phosphorylated in xenografts of SW620 cells after cisplatin treatment; in contrast, phosphorylation was almost undetectable in xenografts of TR3/KD cells, regardless of cisplatin treatment ( Figure 6C ). Furthermore, in the TR3/WT group, the Role of TR3 in cisplatin-induced apoptosis mRNA levels of the BRE and RNF-7 genes were high, and the levels in the cisplatin-treated mice were considerably lower, as expected ( Figure 6D) . However, the levels of BRE and RNF-7 mRNA were nearly unchanged after cisplatin treatment in the xenograft from TR3/ KD cells. Together, these data consistently support our conclusion that TR3 is required for cisplatin-induced cancer cell apoptosis in vivo.
Discussion
Cisplatin-induced apoptosis in melanoma cells has been reported to be TR3 dependent, and the knockdown of TR3 results in a 30% increase in viable cells after cisplatin treatment. In that report, cisplatin was found to induce TR3 mitochondrial translocation and stimulate its interaction with Bcl-2, and the release of cytochrome c contributed to the cisplatin-induced apoptosis of melanoma cells (36) . Here, we established a novel model for TR3-mediated cisplatin-induced apoptosis of colon cancer cells. Upon cisplatin stimulation, TR3 is phosphorylated by Chk2. This modification not only stabilizes TR3 but also promotes TR3 binding to its response elements on the promoters of BRE and RNF-7 and suppresses the expression of these two anti-apoptotic genes, thereby contributing to the induction of apoptosis of cancer cells ( Figure 6E ). Cisplatin can induce the phosphorylation of many proteins by activating kinases, such as PI3K, JNK, ATM and Chk2 (9, 37) . Here, we revealed a novel cross talk between TR3 and Chk2. Pretreatment with a specific inhibitor of Chk2 but not inhibitors of PI3K, JNK, ATM, PKC, ERK or p38 abolished cisplatin-induced TR3 phosphorylation, suggesting that TR3 is a potential substrate of Chk2. The exact phosphorylation site of TR3 by Chk2 is T88. However, the sequence flanking T88 (S-S-A-S-S-pT-S) shares no obvious motif with the highly preferred substrate motif for Chk2 (-hydrophobic-X-R-X-XpS/T-hydrophobic-) (38) , indicating another type of phosphorylation motif for Chk2. In fact, the phosphorylation motifs in many substrates of Chk2 seem flexible. For example, although p53 does not possess a Chk2 consensus site, dimerization or tetramerization of p53 generates an adequate substrate motif for Chk2 phosphorylation (38) .
When stimulated with cisplatin, Chk2-induced phosphorylation efficiently increases the protein level of TR3, which may be attributable to the enhanced protein stability. Similar results have been reported for p53, in which phosphorylation by Chk2 enhanced p53 accumulation by disrupting p53 interaction with the E3 ubiquitin ligase MDM2 under ultraviolet irradiation (39) . Using ChIP and DNA affinity precipitation assays, we proved that the phosphorylation of T88 by Chk2 was essential for TR3 binding to its response element on the promoters of downstream genes. The substitution of T88 completely abolished DNA binding of TR3 even in the presence of cisplatin, thereby leading to a failure of TR3 to regulate the transcription of its target genes. Therefore, Chk2-induced phosphorylation may play dual roles in TR3: first, to stabilize TR3, and second, to strengthen TR3 DNA binding.
Mass of data indicates that TR3 can recruit different cofactors and positively or negatively regulates its downstream genes when stimulated by various stimuli (16, 40) . In the present study, BRE and RNF-7, two pro-survival genes, are newly identified downstream genes of . The mRNA expression levels of TR3, RNF-7 and BRE in xenografts were determined using real-time polymerase chain reaction. (E) A working model to illustrate the role of TR3 in cisplatin-induced apoptosis. When stimulated by cisplatin, activated Chk2 induces the phosphorylation of TR3 at T88. This modification not only inhibits the degradation of TR3 but also enables TR3 binding to its response element on the promoters of BRE and RNF-7, consequently suppressing the transcription of these two anti-apoptotic genes and finally enhancing cisplatin-induced cell apoptosis.
Role of TR3 in cisplatin-induced apoptosis TR3 that are suppressed in response to cisplatin. Cisplatin stimulation induced TR3 binding to the promoters of BRE and RNF-7 and facilitated the recruitment of N-CoR corepressor and finally downregulates the expressions of these two genes. This inhibitory function of TR3 on BRE and RNF-7 may be due to the phosphorylation of TR3 by Chk2 at T88, as T88E, a mimic mutant of TR3 phosphorylation, efficiently inhibited the expression of BRE and RNF-7 even in the absence of cisplatin. This stimulus-dependent TR3 regulation on BRE has also been reported by Wu et al. more recently. They also found that knockdown of TR3 does not obviously influence BRE mRNA level in the absence of deoxycholic acid (DCA). However, with DCA treatment, TR3 became indispensable for upregulating BRE expression in colon cancer cells (41) . DCA is one kind of carcinogen, it can activate ERK (42) . Based on the fact that ERKmediated phosphorylation of TR3 is important for co-activator recruitment (43) , some of the co-activators may be recruited by TR3 to the BRE promoter and consequently upregulate BRE expression in response to DCA. However, in our study, cisplatin is an antitumor agent. When stimulated by cisplatin, TR3 had an ability to recruit co-repressor to the BRE promoter. Therefore, it is possible that different stimuli may activate distinct signal pathway to differentially regulate the functions of TR3.
Several TR3-binding sites (NBRE or NBRE-like) localize on the BRE and RNF-7 promoters. The NBRE sequence located on the BRE promoter contains the cota-nucleotide (AAAGGTCA) that is typically recognized by TR3; the other two TR3-binding sites on the RNF-7 promoter contain point mutations (44) . As a monomer, cisplatin-activated TR3 bound to the inverted copy of the NBRE site with one point mutation on the RNF-7 promoter (located -1011 to -1003 bp), but another binding site (located À467 to À459 bp) with two point mutations showed no TR3 binding, suggesting that two point mutations in the cota-nucleotide disturb the recognition of the response element by TR3. An NBRE on the promoter of the proto-oncogene TCL1 (T-cell leukemia/lymphoma 1) also has two nucleotide bases that are mutated from the core sequences. As a result, the affinity of TR3 for TCL1-NBRE is fairly weak (45) . Our case may be similar, suggesting that subtle changes in the consensus NBRE may affect the DNA-binding ability of TR3. However, the reason why one mutation within the cota-nucleotide sequence does not alter the TR3-DNA interaction remains to be clarified.
Cisplatin is used as a mainstay treatment for many tumors. 5-Fluorouracil is usually combinated with cisplatin for colorectal cancer therapy. Although the targets of 5-fluorouracil are well defined, the clinical utility of cisplatin is limited as the targets for the drug are not well elucidated. Therefore, the discovery of new molecular targets for cisplatin may provide an improved approach to not only better understand the biological mechanisms of cisplatin but also increase cisplatin curative effects in colorectal cancer. FOXO3 is a downstream target of protein kinase B that plays a critical role in cell proliferation and survival. In colon cancer cells, cisplatin-induced FOXO3 dephosphorylation and nuclear translocation are closely related to cell death and drug resistance. The suppression of protein kinase B-mediated FOXO3 phosphorylation using triciribine phosphate or the inhibition of FOXO3 nuclear export using psammaplysene A in cisplatin-resistant HT29 cells resulted in the reduced viability of cancer cells by 30% compared with the group treated with cisplatin alone (46) . Thus, a combination of compounds based on the identified targets may be helpful for cisplatin therapy. In this study, we demonstrate that TR3 is an important target for cisplatin. In a mouse model, cisplatin significantly inhibited intestinal tumorigenesis by reducing adenomas in Apc min/þ mice in a TR3 phosphorylation-dependent manner. In contrast, the knockout of TR3 in Apc min/þ mice sharply abolished the regression of cisplatin-induced adenomas. Together with the fact that TR3 is expressed in most clinical colon tumor samples (47) , it is probably that TR3 may be an important target of cisplatin therapy in intestinal cancer. Accordingly, treatment with cisplatin and a chemical inducer of TR3 could be a viable chemotherapy design for colon cancer.
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